QurAlis

United States
Primghar, Iowa, United States, 02139

Company profile

QurAlis company profile

QurAlis is a clinical-stage biotechnology company that is developing precision medicines with genetically validated targets for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Its proprietary platforms and biomarkers allow for the design and development of drugs that target disease-causing genetic alterations directly.

Business identity

Contact email
[email protected]
Phone number
781-816-7031
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$0-$1M
Founded
2016-12-12

Headquarters

Postal code
02139
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
4
Total equity funding
$135.5M
Last funding
Series B / $88M / 2023-03-09
Last equity funding
Series B / $88M
Investors
19
Lead investors
8
Founders
3
Articles
76

Founders and investors

Founders

Clifford J WoolfKasper RoetKevin Eggan

Lead investors

Dementia Discovery FundDroia VenturesEQT Life SciencesInkefLSP Dementia FundMission BioCapitalPolaris PartnersSanofi Ventures

Investors

Alexandria Venture InvestmentsEQT Life SciencesMission BioCapitalPolaris PartnersSanofi Ventures